# A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

Source: https://onco.cc/trials/nct06244771/  
OnCo record `nct06244771` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of FMC-376 in non-small-cell lung cancer, colorectal cancer and pancreatic ductal adenocarcinoma, run by Frontier Medicines Corporation, now recruiting.

## Summary

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors is a phase 1/2 interventional study registered as NCT06244771 by Frontier Medicines Corporation, with 403 participants planned, started 2024-02-12 and due to reach its primary completion in 2027-10. Interventions recorded: FMC-376.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06244771
- Phase: 1/2
- Setting: An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors
- Sponsor: Frontier Medicines Corporation
- Enrolled: 403

## Sources

- ClinicalTrials.gov NCT06244771: https://clinicaltrials.gov/study/NCT06244771

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- companies: [Frontier Medicines](https://onco.cc/companies/frontier-medicines/)

---
JSON: https://onco.cc/api/v1/entities/nct06244771.json